$RVNC Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Revance Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Revance Therapeutics, Inc.. Get notifications about new insider transactions in Revance Therapeutics, Inc. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 07 2021 | RVNC | Revance Therapeuti ... | Ware Olivia C | Director | Option Exercise | A | 27.91 | 1,268 | 35,390 | 1,268 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Ware Olivia C | Director | Grant | A | 0.00 | 674 | 0 | 7,082 | 6.4 K to 7.1 K (+10.52 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Option Exercise | A | 27.91 | 7,551 | 210,748 | 7,551 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Grant | A | 0.00 | 4,013 | 0 | 23,663 | 19.7 K to 23.7 K (+20.42 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Option Exercise | A | 27.91 | 7,551 | 210,748 | 7,551 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Grant | A | 0.00 | 4,013 | 0 | 20,513 | 16.5 K to 20.5 K (+24.32 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Option Exercise | A | 27.91 | 7,551 | 210,748 | 7,551 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Grant | A | 0.00 | 4,013 | 0 | 19,013 | 15 K to 19 K (+26.75 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Kolaja Carey OConnor | Director | Option Exercise | A | 27.91 | 1,268 | 35,390 | 1,268 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Kolaja Carey OConnor | Director | Grant | A | 0.00 | 674 | 0 | 6,968 | 6.3 K to 7 K (+10.71 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Option Exercise | A | 27.91 | 7,551 | 210,748 | 7,551 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Grant | A | 0.00 | 4,013 | 0 | 20,513 | 16.5 K to 20.5 K (+24.32 %) |
May 07 2021 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Option Exercise | A | 27.91 | 7,551 | 210,748 | 7,551 | |
May 07 2021 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Grant | A | 0.00 | 4,013 | 0 | 19,013 | 15 K to 19 K (+26.75 %) |
Apr 16 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 28.16 | 411 | 11,574 | 65,098 | 65.5 K to 65.1 K (-0.63 %) |
Apr 06 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 28.28 | 2 | 57 | 411,325 | 411.3 K to 411.3 K (0.00 %) |
Mar 17 2021 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Payment of Exercise | F | 27.73 | 2,881 | 79,890 | 49,479 | 52.4 K to 49.5 K (-5.50 %) |
Mar 17 2021 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Payment of Exercise | F | 27.73 | 1,354 | 37,546 | 128,368 | 129.7 K to 128.4 K (-1.04 %) |
Mar 10 2021 | RVNC | Revance Therapeuti ... | Ware Olivia C | Director | Option Exercise | A | 24.03 | 11,161 | 268,199 | 11,161 | |
Mar 10 2021 | RVNC | Revance Therapeuti ... | Ware Olivia C | Director | Grant | A | 0.00 | 6,408 | 0 | 6,408 | 0 to 6.4 K |
Mar 05 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 25.43 | 33,119 | 842,216 | 411,327 | 444.4 K to 411.3 K (-7.45 %) |
Mar 02 2021 | RVNC | Revance Therapeuti ... | Kolaja Carey OConnor | Director | Option Exercise | A | 26.80 | 11,417 | 305,976 | 11,417 | |
Mar 02 2021 | RVNC | Revance Therapeuti ... | Kolaja Carey OConnor | Director | Grant | A | 0.00 | 6,294 | 0 | 6,294 | 0 to 6.3 K |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 28.97 | 1,973 | 57,158 | 68,762 | 70.7 K to 68.8 K (-2.79 %) |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 28.97 | 684 | 19,815 | 70,735 | 71.4 K to 70.7 K (-0.96 %) |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 28.97 | 2,135 | 61,851 | 65,509 | 67.6 K to 65.5 K (-3.16 %) |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 28.97 | 275 | 7,967 | 67,644 | 67.9 K to 67.6 K (-0.40 %) |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Payment of Exercise | F | 28.97 | 2,881 | 83,463 | 129,722 | 132.6 K to 129.7 K (-2.17 %) |
Feb 19 2021 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Payment of Exercise | F | 28.97 | 1,967 | 56,984 | 132,603 | 134.6 K to 132.6 K (-1.46 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Option Exercise | A | 28.01 | 21,540 | 603,335 | 21,540 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Grant | A | 0.00 | 11,905 | 0 | 79,776 | 67.9 K to 79.8 K (+17.54 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Option Exercise | A | 28.01 | 40,925 | 1,146,309 | 40,925 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Grant | A | 0.00 | 22,620 | 0 | 134,570 | 112 K to 134.6 K (+20.21 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Option Exercise | A | 28.01 | 40,925 | 1,146,309 | 40,925 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Grant | A | 0.00 | 22,620 | 0 | 67,919 | 45.3 K to 67.9 K (+49.93 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 28.01 | 40,925 | 1,146,309 | 40,925 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 22,620 | 0 | 71,419 | 48.8 K to 71.4 K (+46.35 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Option Exercise | A | 28.01 | 35,002 | 980,406 | 35,002 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Grant | A | 0.00 | 19,346 | 0 | 52,360 | 33 K to 52.4 K (+58.60 %) |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Option Exercise | A | 28.01 | 73,665 | 2,063,357 | 73,665 | |
Feb 04 2021 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 40,715 | 0 | 810,279 | 769.6 K to 810.3 K (+5.29 %) |
Feb 03 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 25.95 | 33,119 | 859,438 | 444,446 | 477.6 K to 444.4 K (-6.93 %) |
Jan 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 21.36 | 493 | 10,531 | 48,799 | 48.3 K to 48.8 K (+1.02 %) |
Jan 04 2021 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 27.82 | 33,119 | 921,212 | 477,565 | 510.7 K to 477.6 K (-6.49 %) |
Jan 04 2021 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Buy | J | 21.36 | 348 | 7,433 | 45,299 | 45 K to 45.3 K (+0.77 %) |
Dec 22 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 26.75 | 1,556 | 41,623 | 48,306 | 49.9 K to 48.3 K (-3.12 %) |
Dec 22 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 26.75 | 562 | 15,034 | 44,951 | 45.5 K to 45 K (-1.23 %) |
Dec 02 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 23.85 | 33,119 | 789,888 | 510,684 | 543.8 K to 510.7 K (-6.09 %) |
Oct 30 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 26.15 | 33,119 | 865,949 | 543,803 | 576.9 K to 543.8 K (-5.74 %) |
Oct 15 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Payment of Exercise | F | 27.62 | 66,106 | 1,825,848 | 769,564 | 835.7 K to 769.6 K (-7.91 %) |
Oct 15 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 50,913 | 0 | 70,913 | 20 K to 70.9 K (+254.57 %) |
Oct 15 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 264,439 | 0 | 835,670 | 571.2 K to 835.7 K (+46.29 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 25.14 | 6,051 | 152,122 | 45,513 | 51.6 K to 45.5 K (-11.73 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Grant | A | 0.00 | 17,500 | 0 | 51,564 | 34.1 K to 51.6 K (+51.37 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Payment of Exercise | F | 25.14 | 143,269 | 3,601,783 | 571,231 | 714.5 K to 571.2 K (-20.05 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 301,000 | 0 | 714,500 | 413.5 K to 714.5 K (+72.79 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 25.14 | 5,446 | 136,912 | 49,862 | 55.3 K to 49.9 K (-9.85 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 15,750 | 0 | 55,308 | 39.6 K to 55.3 K (+39.81 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Payment of Exercise | F | 25.14 | 7,382 | 185,583 | 111,950 | 119.3 K to 112 K (-6.19 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Grant | A | 0.00 | 17,500 | 0 | 119,332 | 101.8 K to 119.3 K (+17.19 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Payment of Exercise | F | 25.14 | 4,236 | 106,493 | 33,014 | 37.3 K to 33 K (-11.37 %) |
Oct 02 2020 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Grant | A | 0.00 | 12,250 | 0 | 37,250 | 25 K to 37.3 K (+49.00 %) |
Sep 30 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Sell | S | 26.18 | 33,119 | 867,055 | 576,922 | 610 K to 576.9 K (-5.43 %) |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Option Exercise | A | 2.54 | 8,867 | 22,522 | 8,867 | |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Option Exercise | A | 2.54 | 44,828 | 113,863 | 44,828 | |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Grant | A | 0.00 | 57,251 | 0 | 667,292 | 610 K to 667.3 K (+9.38 %) |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Grant | A | 0.00 | 610,041 | 0 | 610,041 | 0 to 610 K |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Option Exercise | A | 2.54 | 8,867 | 22,522 | 8,867 | |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Option Exercise | A | 2.54 | 44,828 | 113,863 | 44,828 | |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Grant | A | 0.00 | 57,251 | 0 | 667,292 | 610 K to 667.3 K (+9.38 %) |
Jul 27 2020 | RVNC | Revance Therapeuti ... | Rankin Aubrey | President, Innovati ... | Grant | A | 0.00 | 610,041 | 0 | 610,041 | 0 to 610 K |
Jul 02 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Buy | J | 13.80 | 1,000 | 13,796 | 34,064 | 33.1 K to 34.1 K (+3.02 %) |
Jul 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 13.80 | 763 | 10,526 | 39,558 | 38.8 K to 39.6 K (+1.97 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Grant | A | 0.00 | 6,000 | 0 | 15,000 | 9 K to 15 K (+66.67 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Grant | A | 0.00 | 6,000 | 0 | 19,650 | 13.7 K to 19.7 K (+43.96 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Grant | A | 0.00 | 6,000 | 0 | 15,000 | 9 K to 15 K (+66.67 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Grant | A | 0.00 | 6,000 | 0 | 16,500 | 10.5 K to 16.5 K (+57.14 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | BYRNES ROBERT F | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | BYRNES ROBERT F | Director | Grant | A | 0.00 | 6,000 | 0 | 16,500 | 10.5 K to 16.5 K (+57.14 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Grant | A | 0.00 | 6,000 | 0 | 16,500 | 10.5 K to 16.5 K (+57.14 %) |
May 15 2020 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Option Exercise | A | 19.40 | 12,000 | 232,800 | 12,000 | |
May 15 2020 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Grant | A | 0.00 | 6,000 | 0 | 16,500 | 10.5 K to 16.5 K (+57.14 %) |
Apr 17 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 14.80 | 432 | 6,394 | 33,064 | 33.5 K to 33.1 K (-1.29 %) |
Mar 17 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President of R ... | Payment of Exercise | F | 15.50 | 1,354 | 20,987 | 101,832 | 103.2 K to 101.8 K (-1.31 %) |
Feb 19 2020 | RVNC | Revance Therapeuti ... | McDowell Caryn Gordon | SVP, GC & Secretary | Payment of Exercise | F | 25.33 | 864 | 21,885 | 23,453 | 24.3 K to 23.5 K (-3.55 %) |
Feb 19 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | COO, President, R&D | Payment of Exercise | F | 25.33 | 3,325 | 84,222 | 103,186 | 106.5 K to 103.2 K (-3.12 %) |
Feb 19 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 25.33 | 576 | 14,590 | 38,795 | 39.4 K to 38.8 K (-1.46 %) |
Feb 19 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 25.33 | 288 | 7,295 | 33,496 | 33.8 K to 33.5 K (-0.85 %) |
Feb 19 2020 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Option Exercise | A | 25.93 | 170,000 | 4,408,100 | 170,000 | |
Feb 19 2020 | RVNC | Revance Therapeuti ... | Moxie Dwight | SVP, GC & Secretary | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 200,000 | 0 | 413,500 | 213.5 K to 413.5 K (+93.68 %) |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 22.32 | 97,500 | 2,176,200 | 97,500 | |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 16,500 | 0 | 39,371 | 22.9 K to 39.4 K (+72.14 %) |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Option Exercise | A | 22.32 | 100,000 | 2,232,000 | 100,000 | |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Grant | A | 0.00 | 20,000 | 0 | 33,784 | 13.8 K to 33.8 K (+145.10 %) |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Option Exercise | A | 22.32 | 146,500 | 3,269,880 | 146,500 | |
Jan 24 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Grant | A | 0.00 | 25,000 | 0 | 106,511 | 81.5 K to 106.5 K (+30.67 %) |
Jan 17 2020 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Payment of Exercise | F | 22.89 | 4,441 | 101,654 | 81,511 | 86 K to 81.5 K (-5.17 %) |
Jan 03 2020 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Buy | J | 10.82 | 382 | 4,133 | 13,784 | 13.4 K to 13.8 K (+2.85 %) |
Jan 03 2020 | RVNC | Revance Therapeuti ... | McDowell Caryn Gordon | SVP, GC & Secretary | Buy | J | 10.82 | 382 | 4,133 | 24,317 | 23.9 K to 24.3 K (+1.60 %) |
Jan 03 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 10.82 | 504 | 5,453 | 22,871 | 22.4 K to 22.9 K (+2.25 %) |
Dec 17 2019 | RVNC | Revance Therapeuti ... | Sjuts Dustin S | Chief Commercial Of ... | Payment of Exercise | F | 15.99 | 576 | 9,210 | 11,492 | 12.1 K to 11.5 K (-4.77 %) |
Dec 17 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 15.99 | 1,556 | 24,880 | 22,367 | 23.9 K to 22.4 K (-6.50 %) |
Dec 17 2019 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Payment of Exercise | F | 15.99 | 2,971 | 47,506 | 85,952 | 88.9 K to 86 K (-3.34 %) |
Oct 15 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Option Exercise | A | 12.18 | 740,000 | 9,013,200 | 740,000 | |
Oct 15 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 200,000 | 0 | 213,500 | 13.5 K to 213.5 K (+1,481.48 %) |
Oct 15 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Option Exercise | A | 12.18 | 740,000 | 9,013,200 | 740,000 | |
Oct 15 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | CEO & President | Grant | A | 0.00 | 200,000 | 0 | 213,500 | 13.5 K to 213.5 K (+1,481.48 %) |
Jul 18 2019 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Option Exercise | A | 12.32 | 18,000 | 221,760 | 18,000 | |
Jul 18 2019 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Grant | A | 0.00 | 9,000 | 0 | 9,000 | 0 to 9 K |
Jul 18 2019 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Option Exercise | A | 12.32 | 18,000 | 221,760 | 18,000 | |
Jul 18 2019 | RVNC | Revance Therapeuti ... | Nolet Chris | Director | Grant | A | 0.00 | 9,000 | 0 | 9,000 | 0 to 9 K |
Jul 02 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 11.02 | 923 | 10,176 | 23,923 | 23 K to 23.9 K (+4.01 %) |
Jul 02 2019 | RVNC | Revance Therapeuti ... | Browne L Daniel | CEO and President | Buy | J | 11.02 | 1,000 | 11,025 | 152,193 | 151.2 K to 152.2 K (+0.66 %) |
Jul 02 2019 | RVNC | Revance Therapeuti ... | McDowell Caryn Gordon | SVP, GC & Secretary | Buy | J | 11.02 | 1,000 | 11,025 | 23,935 | 22.9 K to 23.9 K (+4.36 %) |
Jun 17 2019 | RVNC | Revance Therapeuti ... | McDowell Caryn Gordon | SVP, GC & Secretary | Payment of Exercise | F | 10.86 | 1,383 | 15,019 | 22,935 | 24.3 K to 22.9 K (-5.69 %) |
Jun 06 2019 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Option Exercise | A | 11.24 | 18,000 | 202,320 | 18,000 | |
Jun 06 2019 | RVNC | Revance Therapeuti ... | Beraud Jill | Director | Grant | A | 0.00 | 9,000 | 0 | 9,000 | 0 to 9 K |
May 10 2019 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Gangolli Julian S | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 18,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Foley Mark J | Director | Grant | A | 0.00 | 4,500 | 0 | 13,500 | 9 K to 13.5 K (+50.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | BYRNES ROBERT F | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | BYRNES ROBERT F | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Grant | A | 0.00 | 4,500 | 0 | 13,650 | 9.2 K to 13.7 K (+49.18 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | Vickers Philip J. | Director | Grant | A | 0.00 | 4,500 | 0 | 13,650 | 9.2 K to 13.7 K (+49.18 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | Russell Angus C. | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Option Exercise | A | 12.82 | 9,000 | 115,380 | 9,000 | |
May 10 2019 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
May 10 2019 | RVNC | Revance Therapeuti ... | GARDNER PHYLLIS | Director | Grant | A | 0.00 | 4,500 | 0 | 10,500 | 6 K to 10.5 K (+75.00 %) |
Mar 19 2019 | RVNC | Revance Therapeuti ... | Browne L Daniel | CEO and President | Sell | S | 15.51 | 11,613 | 180,068 | 151,193 | 162.8 K to 151.2 K (-7.13 %) |
Mar 19 2019 | RVNC | Revance Therapeuti ... | Browne L Daniel | CEO and President | Payment of Exercise | F | 15.45 | 2,881 | 44,511 | 162,806 | 165.7 K to 162.8 K (-1.74 %) |
Mar 19 2019 | RVNC | Revance Therapeuti ... | Browne L Daniel | CEO and President | Payment of Exercise | F | 15.45 | 3,256 | 50,305 | 165,687 | 168.9 K to 165.7 K (-1.93 %) |
Mar 19 2019 | RVNC | Revance Therapeuti ... | Allouche Cyril | Principal Accountin ... | Sell | S | 15.48 | 498 | 7,709 | 6,400 | 6.9 K to 6.4 K (-7.22 %) |
Mar 19 2019 | RVNC | Revance Therapeuti ... | Allouche Cyril | Principal Accountin ... | Payment of Exercise | F | 15.45 | 252 | 3,893 | 6,898 | 7.2 K to 6.9 K (-3.52 %) |
Mar 18 2019 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Option Exercise | M | 4.20 | 666 | 2,797 | 0 | |
Mar 18 2019 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Payment of Exercise | F | 15.45 | 1,354 | 20,919 | 88,923 | 90.3 K to 88.9 K (-1.50 %) |
Mar 18 2019 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Payment of Exercise | F | 15.59 | 166 | 2,588 | 90,277 | 90.4 K to 90.3 K (-0.18 %) |
Mar 18 2019 | RVNC | Revance Therapeuti ... | Joshi Abhay | Chief Operating Off ... | Buy | M | 4.20 | 666 | 2,797 | 90,443 | 89.8 K to 90.4 K (+0.74 %) |